Regeneron announces presentations of new data on Eylea HD for retinal disease
pharmafile | February 18, 2026 | News story | Research and Development | Eylea HD, Opthalmology, Regeneron
Regeneron has presented data for Eylea HD (aflibercept) 8mg injection for retinal disease.
The data was presented as part of Regeneron’s opthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting.
Following the previous release of data from the phase 3 QUASAR trial, Eylea HD received approval from the US Food and Drug Administration (FDA) for the treatment of macular oedema following retinal vein occlusion (RVO).
There is also data from the phase 3b ELARA trial of Eylea HD in wet age-related macular degeneration (wAMD) or diabetic macular oedema (DME). The ELARA trial supported approval for monthly treatment, which is needed by a small number of patients, though most use longer dosing intervals. ELARA also demonstrated that switching from anti-vascular endothelial growth factor (anti-VEGF) therapies to Eylea HD improved visual acuity and helped to control retinal swelling.
The most common adverse reactions experienced by patients receiving Eylea HD included cataract, conjunctival haemorrhage and ocular discomfort, pain and irritation.
Boaz Hirshberg, senior vice president, clinical development, internal medicine at Regeneron, said: “[These] presentations further highlight the Eylea HD clinical profile, showcasing its unparalleled durability, while allowing similar efficacy and safety to Eylea 2mg, but with fewer injections.”
He added: “While Eylea HD allows for most patients to achieve longer dosing intervals, data will also be presented from the ELARA trial, supporting Eylea HD approval as a monthly treatment for the small number of patients who need more frequent treatment. Presentations will show that patients who switched to monthly Eylea HD from other anti-VEGF agents generally improved their vision, while also achieving better anatomic control.”
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Dupixent improves symptoms in patients with skin of colour, study shows
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at …
Dupixent approved as first biologic medicine in Japan for COPD patients
The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of …
